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Complete resection is the standard of care for treatment of
thymic malignancies. The use of minimally invasive surgery
remains controversial. We searched online databases and
identiﬁed studies from 1995 to 2014 that compared mini-
mally invasive to open thymectomy for thymic malignancies.
Study end points included operative blood loss, operative
time, respiratory complications, cardiac complications,
length of hospital stay, R0 resection, and recurrence. We
summarized outcomes across studies using random-effects
meta-analysis to account for study heterogeneity. We calcu-
lated ORs for binary outcomes and standardized mean dif-
ferences for continuous outcomes. We calculated incidence
rate ratios for the number of recurrences, accounting for total
person-time observed in each study. Of 516 potential refer-
ence studies, 30 with a total of 2038 patients met the inclu-
sion criteria. Patients with Masaoka stage I or II thymic
malignancy constituted 94.89% of those in the minimally
invasive surgery (MIS) group and 78.62% of those in open
thymectomy (open) group. Mean tumor size was 4.09 cm
(MIS) versus 4.80 (open). Of the 1355 MIS cases, 32 were
converted to open cases. Patients in the MIS group had
signiﬁcantly less blood loss; however, no signiﬁcant differ-
ences in operating time, respiratory complications, cardiac
complications, or overall complications were identiﬁed.
Length of stay was shorter for patients in the MIS group.
WhenpatientswithMasaoka stage I and II thymicmalignancy
only were analyzed, there was no difference in rate of R0
resection or overall recurrence rate. One postoperative death
occurred in the open group. The results of this unadjusted
meta-analysis of published reports comparing minimally
invasive with open thymectomy suggest that in selected pa-
tients with thymic malignancy, minimally invasive thymec-
tomy is safe and can achieve oncologic outcomes similar to
those of open thymectomy.
 2015 International Association for the Study of Lung
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Introduction
Thymic malignancies (thymomas and thymic carci-
nomas) are rare cancers whose etiologies and risk factors
are not well understood.1–13 Complete (R0) surgical resec-
tion is the standard of care for thymic malignancies,
but the safest and most effective method of resection is
controversial.7,9,13–26 Minimally invasive surgery (MIS),
including robotic-assisted thoracoscopic surgery (RATS)
andvideo-assisted thoracoscopic surgery (VATS), is anewer
alternative to open approaches such as median sternotomy
and thoracotomy. Many surgeons are reluctant to adopt
minimally invasive approaches because they are concerned
that such techniques may be associated with increased
manipulation of the tumor and a corresponding risk for
capsular disruption, tumor seeding of the pleura, incom-
plete resection, and increased risk for local recurrence.
Current research suggests that minimally invasive
thymectomy for early-stage thymic malignancies may be
correlated with shorter length of hospital stay (LOS)
and lower intraoperative blood loss than is open
thymectomy.27–34 The literature suggests that minimally
invasive surgery may be as effective as or better than
Figure 1. Minimally invasive versus open thymectomy, open conversion.
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malignancies.25,26,32,33,35,36 Studies have shown com-
parable survival data and oncologic outcomes between
the two procedures30,37,38; however, such claims are
limited by small sample size and lack of long-term
follow-up comparisons between patients who have
undergone MIS and those who have undergone open
thymectomy. In addition, fewer studies focus on thy-
mectomy performed for thymic malignancies as
opposed to including thymectomy performed for
myasthenia gravis.7,8,12,16,19,21,33,36,38–40
The purpose of this meta-analysis is to compare
perioperative and long-term outcome variables between
minimally invasive and open thymectomy for thymic
malignancies by using the current body of literature to
determine whether minimally invasive thymectomy is as
safe and oncologically effective as open surgery.Materials and methods
Search strategy
A thorough literature review of the following online
databaseswas performed: PubMed, ScienceDirect, Oxford
Journals, Springer, Sage Journals, and Ovid. Referencesand related PubMed citations for retrieved articles were
also reviewed for potential inclusion in ourmeta-analysis.
The search period lasted from May 2014 to September
2014, and we used appropriate free text terms, including
thymoma, thymectomy, minimally invasive thymoma,
minimally invasive thymectomy, and minimally invasive
thymic carcinoma, in our search.
Study selection
All the studies included in our meta-analysis of thy-
mectomy for thymic malignancies were published in
English. Studies were analyzed if they detailed a com-
parison between any type of minimally invasive thy-
mectomy and any type of open thymectomy for
thymoma, thymic carcinoma, or both. Not all studies
were included in the analyses for each end point. Studies
with only one arm were included in the evaluation for
demographics (age and gender), tumor characteristics
(stage and size), and open conversion rate.
Any studies indicating minimally invasive thymec-
tomy, open thymectomy, or both for other benign con-
ditions alone (myasthenia gravis and thymolipomas) or
nonthymic malignancies alone (germ cell tumors, lym-
phoma, and lung cancer) were excluded.
Figure 2. Minimally invasive versus open thymectomy, blood loss (mL).
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One investigator independently reviewed each included
article under the guidance of two faculty members from the
same center. Study end points included some or all of the
following: age (years), gender, mean blood loss (milliliters
[mL]), open conversion rate, R0 resection rate, mean oper-
ative time (minutes), mean tumor size (cm), respiratory
complication rate, cardiac complication rate, overall
complication rate, LOS (days), perioperativemortality,mean
follow-up time (months), and locoregional recurrence.
Statistical analysis
To determine quality, the Methodological Index for
Non-Randomized Studies was applied ﬁrst to all the
included studies and then to the comparative studies
only.41 Outcomes were summarized across studies using
random-effects meta-analysis to account for study het-
erogeneity. We calculated ORs for binary outcomes andFigure 3. Minimally invasive versus openstandardized mean differences for continuous outcomes.
Incidence rate ratios (IRR) were calculated for the
number of recurrences, accounting for total person-time
observed in each study.
Results
We identiﬁed 516 references through the aforemen-
tioned search criteria. A total of 30 studies, with publi-
cation dates ranging from 1995 to 2014, contained
pertinent perioperative and long-term outcome infor-
mation regarding one or both modalities of thymectomy
for thymic malignancy. All the included articles were
nonrandomized and retrospective. Methodological Index
for Non-Randomized Studies criteria were applied to all
30 studies (mean 9.87) and then to the 16 comparative
studies exclusively (mean 17.93).
Demographics were calculated using the subset of 16
comparative studies. Mean tumor size was 4.09 cmthymectomy, operative time (minutes).
Figure 4. Minimally invasive versus open thymectomy, length of hospital stay (days).
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to 7.47 cm) for open procedures. Of the 16 comparative
studies, seven examined patients with Masaoka I or II
disease only. For the other nine comparative studies,
80.49% (n ¼ 82) of patients in the MIS group and 66%
(n ¼ 164) of patients in the open group had either
Masaoka stage I or II thymic malignancy. In all 16
comparative studies, 94.89% (n ¼ 841) of patients in the
MIS group and 78.62% (n ¼ 870) of patients in the open
group had Masaoka stage I or II thymic malignancy. The
mean age was 52.34 years (range 47 to 63.1 years) for
patients in the MIS group and 52.72 years (range 47 to
65.4 years) for patients in the open group; 48.52%
(range 35.29% to 63.64%) of patients in the MIS groupFigure 5. Minimally invasive versus openand 47.14% (range 16.67% to 61.11%) of patients in the
open group were men.
Of the 1355 cases in the MIS group, 32 (2.36%) were
converted to open cases, as shown in Figure 1. We
found mean blood loss to be signiﬁcantly less in pa-
tients in the MIS group than in patients in the open
group (226 versus 169 mL, standard difference ¼
–0.78, 95% conﬁdence interval [CI]: –0.97 to 0.57,
p < 0.01), as shown in Figure 2. There was no signiﬁ-
cant difference between patients in the MIS group and
patients in the open group with regard to operative
time (164.92 versus 147.18 minutes, standard
difference ¼ 0.13, 95% CI: –0.28 to 0.54, p ¼ 0.53), as
shown in Figure 3. LOS was shorter for patients in thethymectomy, respiratory complications.
Figure 6. Minimally invasive versus open thymectomy, cardiac complications.
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the open group, standard difference ¼ –0.88, 95% CI:
–1.52 to –0.24, p < 0.01), as shown in Figure 4. There
was no signiﬁcant difference between respiratory
complications (10 in the MIS group versus 18 in the
open group, OR ¼ 0.79, 95% CI: 0.29–2.16, p ¼ 0.64), as
shown in Figure 5. There was also no difference in
terms of cardiac complications (5 in the MIS group
versus 27 in the open group, OR ¼ 0.73, 95% CI:
0.28–1.92, p ¼ 0.52), as shown in Figure 6. Finally,
there was no signiﬁcant difference between patients in
the MIS group and patients in the open group from the
standpoint of overall complication rate (32 in the MISFigure 7. Minimally invasive versus opgroup versus 63 in the open group, OR ¼ 0.90, 95% CI:
0.41–1.93, p ¼ 0.78), as shown in Figure 7.
Additionally, there was no signiﬁcant difference in R0
resection rate (OR ¼ 0.82, 95% CI: 0.38–1.73, p ¼ 0.60),
as shown in Figure 8. There was no signiﬁcant difference
in rate of locoregional recurrence (IRR ¼ 1.57, 95% CI:
0.47–5.26, p ¼ 0.46), as shown in Figure 9. In the subset
of patients with Masaoka stage I or II thymic malignancy,
there was no difference in R0 resection rate (n ¼ 711,
97.36% versus 97.25%, OR ¼ 0.98, 95% CI: 0.23–4.14,
p ¼ 0.88) or locoregional recurrence rate (n ¼ 234,
2.86% versus 2.91%, IRR ¼ 2.10, 95% CI: 0.39–11.25,
p ¼ 0.39), as shown in Figures 10 and 11.en thymectomy, all complications.
Figure 8. Minimally invasive versus open thymectomy, R0 resections.
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Minimally invasive surgical techniques have become
more widely adopted in some areas of thoracic surgery
as the results of clinical series of patients with lung and
esophageal cancers have become more mature. However,
many surgeons remain reluctant to adopt minimally
invasive surgical techniques for the treatment of patients
with thymic malignancies for several reasons. Perhaps
most commonly, critics have stated that MIS could lead
to incomplete resection or tumor seeding and therefore
to higher local recurrence rates and lower overall sur-
vival rates. We systematically identiﬁed and evaluated
the existing data comparing the clinical outcomes of
minimally invasive thymectomy to open thymectomy by
using the techniques of meta-analysis. Because of theFigure 9. Minimally invasive versus openscarcity of available data on long-term survival and
inasmuch as complete resection is an important deter-
minant of recurrence-free survival in patients with
thymic malignancy,12,14 we focused on complete resec-
tion rates and limited local recurrence data as surrogate
oncologic outcome measures.
We found that there is no statistically signiﬁcant
difference in R0 resections overall in either the MIS or
open groups, although the trend favored patients in the
MIS group. The only statistically signiﬁcant clinical out-
comes that we observed were decreased blood loss and
shorter LOS, both of which favored the minimally inva-
sive group. We observed no differences in operating time
or complications between the two groups. Because pa-
tients with larger tumors would more likely be assignedthymectomy, locoregional recurrences.
Figure 10. Minimally invasive versus open thymectomy, Masaoka stage I–II subset, R0 resections.
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evaluation of patients whose malignancy was clinically
staged by the investigators of the various trials as
Masaoka I and II disease and found no difference be-
tween R0 resection rates in this smaller subset of pa-
tients. Data on local recurrence was mentioned in only a
few of the published reports on patients with tumors at
an early clinical stage. On the basis of these limited data,
we observed no difference between the two groups from
the standpoint of local recurrence rates, although sub-
sequent examination of recurrence in patients whose
minimally invasive surgical procedure was converted to
open should be explored.
In addition, our meta-analysis is limited by the in-
clusion of only nonrandomized, retrospective studies. In
our literature review we found no randomized or pro-
spective studies that met our criteria. Furthermore, there
is a paucity of long-term follow-up data for patients who
have undergone thymectomy for thymic malignancies.
Our analysis was constrained by the inability to perform
propensity matching because of small aggregate sample
size and difﬁculty in obtaining individual patient infor-
mation from the included studies. These factors led toincreased heterogeneity within the analysis. Finally, the
decision to pursue total versus subtotal, or partial, thy-
mectomy is another factor to be considered. Although
subtotal thymectomy for thymoma has shown results
comparable to those of total thymectomy,42 further an-
alyses should be performed to conﬁrm these ﬁndings.
We generally recommend total thymectomy in all cases
of thymoma.
From this analysis we were unable to identify factors
that would help surgeons select appropriate patients for
minimally invasive as opposed to open thymectomy
approaches. Certainly, if initial attempts at minimally
invasive surgical resection are deemed by the surgeon to
be unlikely to lead to a complete resection or to violate
any other principles of oncologic surgery, then conver-
sion to open thymectomy surgery should be performed.
Interestingly, conversion to open surgery was reported
in only 2.4% of cases in our review, thus suggesting that
given similar rates of R0 resection, most of the surgeons
had appropriately selected patients for minimally inva-
sive thymectomy. On the basis of the ﬁndings of this
meta-analysis, we conclude that for selected patients,
minimally invasive thymectomy is safe and can achieve
Figure 11. Minimally invasive versus open thymectomy, Masaoka stage I–II subset, locoregional recurrences.
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open thymectomy operations. Because of the indolent
nature of thymic malignancies, long-term follow-up is
especially critical in determining efﬁcacy of surgery. Data
on long-term cancer-speciﬁc outcomes awaits the
mature results of longitudinal studies and international
efforts such as the International Thymic Malignancy In-
terest Group database.References
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